Healthy AdultsEarly Phase 1NCT07285629
Safety and Efficacy of Klotho and Follistatin Gene Therapy
A Early Phase 1 study testing Follistatin and klotho gene therapy in people with Healthy Adults, run by Minicircle at 2 sites in 2 countries.
Trial summary
The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy. Read more about this study
- Who is it for?
- Ages 50 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Adults
- What is being tested?
- Follistatin and klotho gene therapy
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 14 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 16 Dec 2025to 30 Apr 2026
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 50 to 80 years
- General good health
- Willing to comply with all study-related procedures and visits
- Participant is open to morphological change
- If female, participant agrees to maintain contraception
- If female, participant agrees to take a pregnancy test
- If female, participant agrees to a pregnancy waiver
Who cannot join
- Currently enrolled in another clinical trial
- History of cancer, autoimmune disease, or chronic kidney/liver disease
- Use of immunosuppressive therapy
- Pregnant or breastfeeding
- Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study.
- Regular use of NMDA (N-methyl-D-aspartate) antagonists (i.e., memantine, ketamine, etc.)
Show all 9Show fewer
- Regular use of antiplatelet medications (i.e., aspirin)
- Any medical or psychiatric condition that could interfere with participation or pose safety concerns
- Unwilling or unable to provide informed consent
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
Honduras1 site
Global Alliance of Regenerative Medicine (GARM) Clinic
Roatán, Bay Islands
About this study
Official title: Evaluating the Safety and Efficacy of Injectable Combination Klotho and Follistatin Plasmid Gene Therapy in Humans -- An Interventional, Non-Placebo Controlled Pilot Phase Study
The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.
Read the detailed description
Healthy participants will take part in cognitive and health testing before and after administration of plasmid-delivered nonviral klotho and follistatin gene therapy. The method of administration will be subcutaneous injection into abdominal fat deposits. Klotho and follistatin plasmid gene therapy have the potential to improve physical function, cognitive function, kidney function, body composition, epigenetic age, and subjective well being.
Note that the investigational product will be administered at a site outside of the U.S. which is not under FDA jurisdiction, and only non-treatment pre/post outcome assessments (e.g., cognitive assessments or blood sample collection) occur at the U.S. site.
- Conditions
- Healthy Adults
- Being tested
- Follistatin and klotho gene therapy
- Keywords
- klotho, follistatin, nonviral, gene therapy, plasmid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Follistatin and klotho gene therapyGenetic
Injection of nonviral plasmid-delivered follistatin and klotho gene therapy
| Study group | Role | What they receive |
|---|---|---|
| Intervention with Cognitive/Health battery before and after | Experimental | This arm includes cognitive and health battery pre- and post-intervention of the gene therapy Receives: Genetic: Follistatin and klotho gene therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentration of Serum α-Klotho Measured by Enzyme-Linked Immunosorbent Assay (ELISA) (pg/mL)
Serum α-Klotho protein concentration will be quantified using a validated ELISA. Results will be determined from picograms per milliliter (pg/mL) for each participant at each time point. Higher or lower values have no inherent directionality and will be interpreted in study context.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Serum Follistatin Measured by Enzyme-Linked Immunosorbent Assay (ELISA) (pg/mL)
Serum follistatin concentration will be quantified using a validated ELISA. Results will be reported as picograms per milliliter (pg/mL) for each participant at each time point. Higher or lower values have no inherent directionality and will be interpreted in study context.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Number and Percentage of Participants Experiencing Treatment-Emergent Adverse Events as Assessed by Patient-Reported Outcomes Version of Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Assessed through a checklist version of the PRO-CTCAE with each symptom options being none, mild, moderate, or severe. Items will be scored with 0, 1, 2, 3 respectively. Item responses will be summarized as number and percentage of participants experiencing each adverse event by system/organ class. High scores indicate highest severity of symptoms and low scores indicate no symptoms.
Measured: Within 1 week after treatment and then 1 month, 2 months, and 3 months after treatment
Secondary outcomes (32)
Change From Baseline in World Health Organization Quality of Life Brief Version (WHOQOL-BREF) Domain Scores (0-100)
The WHOQOL-BREF is a self-report questionnaire that includes four domains: Physical Health, Psychological, Social Relationships, and Environment. Each domain score is transformed to a 0-100 scale, with higher scores indicating better quality of life. Changes from baseline will be examined per domain.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Change From Baseline in Pattern Comparison Processing Speed Test T-Score (Mean 50 ± 10)
The Pattern Comparison Processing Speed Test measures processing speed using age-adjusted T-scores (mean 50, SD 10). Higher scores reflect faster cognitive processing. Changes from baseline will be analyzed per participant and time point.
Measured: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change From Baseline in Picture Sequence Memory Test T-Score, Forms A and B (Mean 50 ± 10)
Picture Sequence Memory Test evaluates episodic memory. Each form (A and B) yields an age-adjusted T-score (mean 50, SD 10). Higher scores indicate better memory performance. Forms A and B will be averaged.
Measured: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change From Baseline in Flanker Inhibitory Control and Attention Test T-Score (Mean 50 ± 10)
The Flanker Inhibitory Control and Attention Test measures inhibitory control and attention. Scores are age-adjusted T-scores (mean 50, SD 10). Higher scores indicate better performance. Changes from baseline will be analyzed per participant and time point.
Measured: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change From Baseline in Dimensional Change Card Sort Test T-Score (Mean 50 ± 10)
The Dimensional Change Card Sort Test assesses cognitive flexibility. Scores are age-adjusted T-scores (mean 50, SD 10). Higher scores indicate better executive function. Changes from baseline will be analyzed per participant and time point.
Measured: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change From Baseline in Picture Vocabulary Test T-Score (Mean 50 ± 10)
Picture Vocabulary Test measures receptive vocabulary. Results are expressed as age-adjusted T-scores (mean 50, SD 10), with higher scores indicating better performance. Change from baseline will be analyzed per participant and time point.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Epigenetic Biological Age Estimated From Whole-Genome Deoxyribonucleic Acid (DNA) Methylation Profiles (change from baseline) (years)
Whole-blood DNA methylation will be measured using bisulfite sequencing performed by Generation Lab. Epigenetic biological age will be computed from these methylation data using validated algorithms. Age estimates will be expressed in years. Lower epigenetic age relative to chronological age indicates younger biological status.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Timed one leg stance change from baseline (seconds)
Duration (seconds) that the participant can maintain an unsupported one-leg stance on the left and right leg separately, measured from the point of foot lift until loss of balance or foot contact with the ground.
Measured: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change from baseline in number of squats performed (count)
Total number of full squats the participant can complete with proper form within a continuous, unassisted trial, measured from the start of movement until the participant stops or is unable to continue.
Measured: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change from baseline in number of push-ups performed (count)
Total number of standard push-ups completed with proper form in a continuous trial, counted from the first repetition until the participant stops or is unable to continue.
Measured: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Number of sit-ups performed (change from baseline) (count)
Total number of sit-ups the participant can complete with proper form in a continuous trial, measured from the first repetition until the participant stops or is unable to continue.
Measured: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change from Baseline: Concentration of High-Sensitivity C-Reactive Protein (hs-CRP) Measured by Immunoturbidimetric Assay (mg/L)
hs-CRP will be measured using an immunoturbidimetric assay and expressed in mg/L. hs-CRP is a marker of systemic inflammation and cardiovascular risk.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Ionized Calcium Measured by Ion-Selective Electrode (mmol/L)
Ionized calcium will be measured using an ion-selective electrode analyzer. Results will be reported in millimoles per liter (mmol/L) and represent physiologically active calcium fraction.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Serum Cystatin C Measured by Immunoassay (mg/L)
Serum Cystatin C will be measured using a standardized immunoassay and reported in mg/L for each participant and time point. Cystatin C is a biomarker of glomerular filtration rate and provides a mechanistic link between α-Klotho activity and renal function.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Serum Phosphorus Measured by Clinical Chemistry Analyzer (mg/dL)
Serum inorganic phosphorus will be measured on a standard clinical chemistry analyzer. Results will be reported in mg/dL for each participant and time point. Phosphorus levels reflect systemic phosphate homeostasis influenced by α-Klotho and FGF23 activity.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Urinary Phosphate Excretion Measured by Clinical Chemistry Assay (mg/24 h or mg/g Creatinine)
Urinary phosphate will be assessed using a validated chemistry assay. Will be expressed either as total phosphate excretion in milligrams per 24 hours (mg/24 h) or as the phosphate-to-creatinine ratio (mg phosphate per g creatinine). This measure reflects renal handling of phosphate and functional effects of α-Klotho on phosphate excretion.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Intact Parathyroid Hormone Measured by Two-Site Immunoassay (pg/mL)
Intact Parathyroid Hormone (PTH) will be measured in serum using a two-site immunoassay that detects the full-length molecule. Results will be reported in picograms per milliliter (pg/mL) per participant and time point. PTH reflects parathyroid activity within the α-Klotho-FGF23-vitamin D feedback pathway.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Serum 1,25-Dihydroxyvitamin D (Calcitriol) Measured by Liquid Chromatography-Tandem Mass Spectrometry (pg/mL)
Serum 1,25-dihydroxyvitamin D (calcitriol) will be quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Concentrations will be expressed in picograms per milliliter (pg/mL). This hormone regulates calcium and phosphate balance and is a downstream marker of α-Klotho-FGF23-PTH axis modulation.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Comprehensive Metabolic Panel (Safety Laboratory Assessment)
A standard comprehensive metabolic panel (CMP) will be collected to evaluate general metabolic and organ function for safety monitoring. The standard panel includes 14 markers: Glucose, calcium, sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine (serum), albumin, total protein, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, and total bilirubin. Individual components will be assessed clinically to ensure no major changes to health stability but these will not analyzed as specific study endpoints.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Platelet Factor 4 (PF4) Measured by Enzyme-Linked Immunosorbent Assay (ELISA) (ng/mL or OD Units)
Platelet Factor 4 (PF4) will be measured using a validated ELISA and reported as nanograms per milliliter (ng/mL) or optical density (OD) units. PF4 is a marker of platelet activation and potential immune-mediated coagulation effects.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Cardio IQ® Fibrinogen Antigen (mg/dL)
Fibrinogen antigen concentration will be measured by nephelometry using the Cardio IQ® assay. Reported in milligrams per deciliter (mg/dL).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Hemoglobin A1c (%) change from baseline
Hemoglobin A1c (HbA1c) will be measured by standardized assay methods and reported as percent (%). Estimated average glucose (eAG) will be reported alongside HbA1c for interpretability only and will be derived from the HbA1c value using a validated conversion formula. eAG is not independently measured. Change from baseline HbA1c will be reported as a percentage and the corresponding eAG value will be included for interpretability.
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Homocysteine change from baseline (µmol/L)
Plasma homocysteine concentration will be measured by immunoassay or chromatography-based methods and reported in micromoles per liter (µmol/L).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Asymmetric and Symmetric Dimethylarginine (ADMA/SDMA) change from baseline (µmol/L)
Plasma ADMA and SDMA will be quantified by mass spectrometry-based assay and reported in micromoles per liter (µmol/L).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Serum Interleukin-6 (IL-6) change from baseline (pg/mL)
Serum IL-6 levels will be measured by high-sensitivity immunoassay and reported in picograms per milliliter (pg/mL).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Tumor Necrosis Factor-α (TNF-α) change from baseline (pg/mL)
Serum TNF-α concentration will be measured by immunoassay and reported in picograms per milliliter (pg/mL).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Serum Interleukin-1β (IL-1β) change from baseline (pg/mL)
Serum IL-1β levels will be quantified using a cytokine immunoassay and reported in picograms per milliliter (pg/mL).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Serum Interferon-γ (IFN-γ) (pg/mL)
Plasma IFN-γ concentration will be measured using an immunoassay and reported in picograms per milliliter (pg/mL).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Serum Interleukin-10 (IL-10) (pg/mL)
Serum IL-10 levels will be measured by cytokine immunoassay and reported in picograms per milliliter (pg/mL).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Myostatin (ng/mL)
Serum myostatin concentration will be measured using a validated immunoassay and reported in nanograms per milliliter (ng/mL).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Activin A (pg/mL)
Serum activin A will be quantified by immunoassay and reported in picograms per milliliter (pg/mL).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Insulin-Like Growth Factor-1 (IGF-1) (ng/mL)
Serum IGF-1 will be measured using a standardized immunoassay with age-adjusted calibration and reported in nanograms per milliliter (ng/mL).
Measured: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2025
- Study start16 Dec 2025
- Primary completion30 Apr 2026
- Study completion30 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Non-placebo-controlled
- Masking
- None (open label)
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- Minicircle
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07285629
- Sponsor's protocol ID
- GIFIRB202507313
- Status last verified
- Dec 2025
- First submitted
- 27 Nov 2025
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data will be made available along with a data dictionary describing each variable. If the study results in multiple publications, the IPD corresponding to the measures reported in each publication will be shared upon that publication. The complete trial dataset, if anything is remaining, will be made available once all results have been published. Supporting documentation shared will include study protocol, statistical analysis plan, informed consent forms, and analytic code.
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Safety and Efficacy of Injectable Combination Klotho and Follistatin Plasmid Gene Therapy in Humans -- An Interventional, Non-Placebo Controlled Pilot Phase Study
- ClinicalTrials.gov ID
- NCT07285629
- Acronym / sponsor ID
- GIFIRB202507313
- Conditions
- Healthy Adults
- Keywords
- klotho, follistatin, nonviral, gene therapy, plasmid
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- MinicircleIndustry (pharma, biotech, devices)
- Study start
- 16 Dec 2025 (actual)
- Primary completion
- 30 Apr 2026 (actual)
- Study completion
- 30 Apr 2026 (actual)
- First posted
- 16 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.
Detailed description
Healthy participants will take part in cognitive and health testing before and after administration of plasmid-delivered nonviral klotho and follistatin gene therapy. The method of administration will be subcutaneous injection into abdominal fat deposits. Klotho and follistatin plasmid gene therapy have the potential to improve physical function, cognitive function, kidney function, body composition, epigenetic age, and subjective well being.
Note that the investigational product will be administered at a site outside of the U.S. which is not under FDA jurisdiction, and only non-treatment pre/post outcome assessments (e.g., cognitive assessments or blood sample collection) occur at the U.S. site.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Non-placebo-controlled
| Arm | Type | Receives |
|---|---|---|
| Intervention with Cognitive/Health battery before and after | Experimental | Genetic: Follistatin and klotho gene therapyThis arm includes cognitive and health battery pre- and post-intervention of the gene therapy |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adults aged 50 to 80 years
- General good health
- Willing to comply with all study-related procedures and visits
- Participant is open to morphological change
- If female, participant agrees to maintain contraception
Key exclusion criteria (9 listed)
- Currently enrolled in another clinical trial
- History of cancer, autoimmune disease, or chronic kidney/liver disease
- Use of immunosuppressive therapy
- Pregnant or breastfeeding
- Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Follistatin and klotho gene therapyInjection of nonviral plasmid-delivered follistatin and klotho gene therapy | Genetic | Intervention with Cognitive/Health battery before and after |
Primary outcome
Concentration of Serum α-Klotho Measured by Enzyme-Linked Immunosorbent Assay (ELISA) (pg/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Serum α-Klotho protein concentration will be quantified using a validated ELISA. Results will be determined from picograms per milliliter (pg/mL) for each participant at each time point. Higher or lower values have no inherent directionality and will be interpreted in study context.
Concentration of Serum Follistatin Measured by Enzyme-Linked Immunosorbent Assay (ELISA) (pg/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Serum follistatin concentration will be quantified using a validated ELISA. Results will be reported as picograms per milliliter (pg/mL) for each participant at each time point. Higher or lower values have no inherent directionality and will be interpreted in study context.
Number and Percentage of Participants Experiencing Treatment-Emergent Adverse Events as Assessed by Patient-Reported Outcomes Version of Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Time frame: Within 1 week after treatment and then 1 month, 2 months, and 3 months after treatment
Assessed through a checklist version of the PRO-CTCAE with each symptom options being none, mild, moderate, or severe. Items will be scored with 0, 1, 2, 3 respectively. Item responses will be summarized as number and percentage of participants experiencing each adverse event by system/organ class. High scores indicate highest severity of symptoms and low scores indicate no symptoms.
32 secondary outcomes
Change From Baseline in World Health Organization Quality of Life Brief Version (WHOQOL-BREF) Domain Scores (0-100)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Change From Baseline in Pattern Comparison Processing Speed Test T-Score (Mean 50 ± 10)
Time frame: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change From Baseline in Picture Sequence Memory Test T-Score, Forms A and B (Mean 50 ± 10)
Time frame: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change From Baseline in Flanker Inhibitory Control and Attention Test T-Score (Mean 50 ± 10)
Time frame: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change From Baseline in Dimensional Change Card Sort Test T-Score (Mean 50 ± 10)
Time frame: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change From Baseline in Picture Vocabulary Test T-Score (Mean 50 ± 10)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Epigenetic Biological Age Estimated From Whole-Genome Deoxyribonucleic Acid (DNA) Methylation Profiles (change from baseline) (years)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Timed one leg stance change from baseline (seconds)
Time frame: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change from baseline in number of squats performed (count)
Time frame: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change from baseline in number of push-ups performed (count)
Time frame: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Number of sit-ups performed (change from baseline) (count)
Time frame: From 1 month prior to treatment to 3 months after treatment (4 timepoints)
Change from Baseline: Concentration of High-Sensitivity C-Reactive Protein (hs-CRP) Measured by Immunoturbidimetric Assay (mg/L)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Ionized Calcium Measured by Ion-Selective Electrode (mmol/L)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Serum Cystatin C Measured by Immunoassay (mg/L)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Serum Phosphorus Measured by Clinical Chemistry Analyzer (mg/dL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Urinary Phosphate Excretion Measured by Clinical Chemistry Assay (mg/24 h or mg/g Creatinine)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Intact Parathyroid Hormone Measured by Two-Site Immunoassay (pg/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Serum 1,25-Dihydroxyvitamin D (Calcitriol) Measured by Liquid Chromatography-Tandem Mass Spectrometry (pg/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Comprehensive Metabolic Panel (Safety Laboratory Assessment)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Concentration of Platelet Factor 4 (PF4) Measured by Enzyme-Linked Immunosorbent Assay (ELISA) (ng/mL or OD Units)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Cardio IQ® Fibrinogen Antigen (mg/dL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Hemoglobin A1c (%) change from baseline
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Homocysteine change from baseline (µmol/L)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Asymmetric and Symmetric Dimethylarginine (ADMA/SDMA) change from baseline (µmol/L)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Serum Interleukin-6 (IL-6) change from baseline (pg/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Tumor Necrosis Factor-α (TNF-α) change from baseline (pg/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Serum Interleukin-1β (IL-1β) change from baseline (pg/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Serum Interferon-γ (IFN-γ) (pg/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Serum Interleukin-10 (IL-10) (pg/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Myostatin (ng/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Activin A (pg/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Insulin-Like Growth Factor-1 (IGF-1) (ng/mL)
Time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
- Individual participant dataSharing planned: Yes. Individual participant data will be made available along with a data dictionary describing each variable. If the study results in multiple publications, the IPD corresponding to the measures reported in each publication will be shared upon that publication. The complete trial dataset, if anything is remaining, will be made available once all results have been published. Supporting documentation shared will include study protocol, statistical analysis plan, informed consent forms, and analytic code.
Related trials for Healthy Adults
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Follistatin and klotho gene therapy in people with Healthy Adults, run by Minicircle at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, Honduras. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentration of Serum α-Klotho Measured by Enzyme-Linked Immunosorbent Assay (ELISA) (pg/mL) (time frame: From 1 month prior to treatment to 3 months after treatment (5 timepoints)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.